Numerous Mounjaro lawsuits alleging severe side effects have been consolidated in a federal multidistrict litigation (MDL). The lawsuits against Mounjaro allege Eli Lilly and Company failed to warn consumers about the risk of gastroparesis, stomach paralysis, ileus, gallbladder removal, and other side effects after taking Mounjaro for weight loss.
Mounjaro lawyers believe the litigation alleging harmful side effects associated with weight loss drugs will grow to include hundreds or thousands of plaintiffs.
If you or a member of your family took Mounjaro for weight loss and experienced side effects like gastroparesis (stomach paralysis), gastroenteritis, vomiting, nausea, or diarrhea, you may qualify for a case. Our firm has partnered with leading attorneys representing claimants who have experienced severe side effects after taking Mounjaro for weight loss. We offer free Mounjaro case evaluations.
To see if you qualify for a Mounjaro lawsuit, call us today at (310) 207-3233 or fill out our free and confidential case evaluation.
Mounjaro Lawsuit Update 2025
June 3, 2025: There are 1,882 GLP-1 claims in the federal MDL, many of which involve Mounjaro.
May 14, 2025: Daubert hearings began today in the federal GLP-1 litigation. U.S. District Judge Karen S. Marston will assess whether expert witness reports and evidence are legally admissible in court. If Judge Marston rules that expert witnesses used valid methodologies to arrive at their scientific conclusions, they will be permitted to testify in court, and the litigation will proceed.
May 3, 2025: Hundreds of cases have been added to the MDL since the start of 2025, bringing the total to 1,809.
April 4, 2025: There are 1,685 GLP-1 lawsuits against drug manufacturers in the federal MDL. Mounjaro attorneys say bellwether planning and pretrial motions are underway.
March 23, 2025: Plaintiffs in the federal GLP-1 MDL filed an opposition to the drug maker defendants’ motion to dismiss claims that Mounjaro and other similar drugs cause gastroparesis and other serious side effects.
March 3, 2025: Mounjaro lawyers participated in a status conference for the federal MDL. Attorneys outlined the short-form complaint process to streamline documentation for plaintiffs, and the Rule 702 hearing date is set for May 14, 2025.
February 11, 2025: The GLP-1 RA Products Liability MDL has grown to 1,443 pending cases before Judge Karen S. Marston in Pennsylvania. The surge in cases parallels Eli Lilly's recent announcement of a 45% revenue increase to $13.53 billion, mainly driven by Mounjaro sales. As the medication's use continues to expand, more injury claims are expected.
January 30, 2025: Eli Lilly filed a motion to dismiss portions of the master complaint, though notably did not challenge failure-to-warn claims.
January 10, 2025: A crucial Rule 702 evidentiary hearing has been scheduled for May 14, 2025. The court will evaluate the admissibility of expert testimony on causation. This hearing represents a critical juncture in the litigation, as the judge will determine whether plaintiffs' expert opinions will be allowed in court.
December 3, 2024: Plaintiffs in the federal GLP-1 MDL have filed a Master Complaint outlining common allegations against the drug maker defendants, including Eli Lilly, the manufacturer of Mounjaro.
Individuals in federal Mounjaro lawsuits allege the following side effects:
- Gastroparesis
- Ischemic Bowel
- Necrotizing Pancreatitis
- Gallbladder Disease
- Deep Vein Thrombosis
- Pulmonary Embolism
- Micronutrient Deficiencies
- Wernicke’s Encephalopathy
- Aspiration of Gastric Contents
The judge overseeing federal cases will soon decide on the bellwether process for trying cases.
October 3, 2024: Over 1,090 cases are pending in the GLP-1 MDL, which includes lawsuits against Mounjaro. This is a significant jump in cases over the last several weeks.
August 5, 2024: There are 346 cases in the GLP-1 MDL. The next status conference will be held on August 8, 2024.
July 25, 2024: The number of GLP-1 lawsuits in the federal MDL increased to 105 cases. Because of a new order that allows lawyers to file complaints directly into MDL No. 3094, we anticipate the number of cases to steadily increase in the next few months.
June 11, 2024: The JPML selected a new judge to oversee the GLP-1 products liability MDL, which includes lawsuits against Mounjaro and other similar weight loss drugs. After the sudden passing of U.S. District Judge Gene Pratter, U.S. District Judge Karen Marston will now manage the MDL.
The GLP-1 drug litigation grew slightly over the last month with 101 lawsuits now consolidated in the MDL. We believe there will be an influx in these cases over the next few months.
May 6, 2024: The most recent MDL statistics report lists 87 cases in the Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation. The lawsuits, which are consolidated before Judge Gene E.K. Pratter in the Eastern District of Pennsylvania, allege a variety of gastrointestinal side effects after taking Mounjaro, including gastroparesis.
April 3, 2024: Lawyers representing individuals who allege harm after taking Mounjaro for weight loss participated in a status conference last month in Pennsylvania federal court. U.S. District Court for the Eastern District of Pennsylvania is the venue for all federally filed Mounjaro lawsuits.
Most of the lawsuits were filed by individuals who experienced gastroparesis after taking Mounjaro. What is gastroparesis? It is a medical condition that causes delayed stomach emptying. Symptoms include severe nausea, vomiting, gastrointestinal burning, and other painful side effects.
Not all Mounjaro lawsuits will end up in the weight loss drug MDL. Some cases have already been filed in New Jersey state court.
February 5, 2024: The Judicial Panel on Multidistrict Litigation (JPML) issued an order to consolidate dozens of lawsuits alleging harm after taking Mounjaro, Ozempic, and similar medications. Consolidated cases will now be a part of MDL 3094 In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAS) Products Liability Litigation before Judge Gene E. K. Pratter for the Eastern District of Pennsylvania.
The JPML chose to include both Eli Lilly and Novo Nordisk in the litigation. Judge Pratter can separate the defendants should he deem it appropriate, but for now, lawsuits alleging harm after taking Ozempic, Mounjaro, Rybelsus, and Wegovy will be a part of the MDL.
We will know which lawyers will serve on the plaintiffs’ leadership in the coming weeks.
January 25, 2024: The Judicial Panel on Multidistrict Litigation (JPML) heard arguments concerning plaintiffs' request to consolidate lawsuits alleging harm after taking Mounjaro and similar drugs. into a multidistrict litigation (MDL). If an MDL is granted, it remains to be seen whether the litigation will involve all GLP-1 agonists. The panel may decide to separate claims based on which drug companies are implicated.
January 2, 2024: Lawyers anticipate a decision on whether the court will establish a federal MDL for lawsuits alleging severe side effects after taking Mounjaro.
December 22, 2023: A patient in Louisiana recently filed a lawsuit against pharmaceutical giants Eli Lilly & Co. and Novo Nordisk alleging Mounjaro and Ozempic caused severe side effects, including vomiting and tooth loss.
Defendants are challenging the Louisiana court jurisdiction, arguing the lawsuit fails to establish a connection between the companies and the state of Louisiana. They further assert that attorneys for the plaintiff failed to provide prescription history, marketing claims, or other allegations pertaining to the state of Louisiana in the Mounjaro lawsuit.
The plaintiff seeks to consolidate lawsuits involving Ozempic and Mounjaro filed in federal court. The decision to consolidate the cases into a multidistrict litigation (MDL) could come in January 2024.
December 2, 2023: A motion was recently filed with the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all federal cases alleging serious side effects after taking Mounjaro, Ozempic, Wegovy, and similar drugs. If the motion is granted, the court will consolidate all federal cases filed before one judge in one court.
October 21, 2023: A new study published in the Journal of the American Medical Association (JAMA) found that individuals using popular weight loss medications may face an increased risk of serious gastrointestinal issues. Per the study, “the use of GLP-1 agonists for weight loss compared with use of bupropion-naltrexone was associated with increased risk of pancreatitis, gastroparesis, and bowel obstruction…”
What is Mounjaro (Tirzepatide)?
Tirzepatide, marketed as Mounjaro, received U.S. Food and Drug Administration (FDA) approval in May 2022 for the treatment of type 2 diabetes. Less than five months later, Eli Lilly announced that the FDA “granted Fast Track designation for the investigation of tirzepatide” to treat obese or overweight adults. The announcement came as a similar drug, Ozempic (generic semaglutide), was heavily promoted for weight loss even though it was only approved as a diabetes medication.
Administered through subcutaneous injections, tirzepatide regulates blood glucose levels and improves overall blood-sugar control. The drug's mechanism of action revolves around the activation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These receptors play a crucial role in controlling blood sugar levels after meals.
As a GIP-analogue, Mounjaro activates both GLP-1 and GIP receptors simultaneously, which has the potential to cause unforeseen complications. While Mounjaro has gained popularity within a short amount of time (especially for weight loss), it is important to remain mindful of the potential side effects, which may overshadow the positive outcomes.
How Much Does Mounjaro Cost?
Eli Lilly’s list price for Mounjaro is $1,023.04 per fill, which includes four pre-filled pens, designed to last one month. To put that into perspective, patients may find themselves forking over a staggering $13,299.52 per year for Mounjaro.
The list price reflects the amount at which Eli Lilly sells Mounjaro to pharmacies and retailers, which does not accurately reflect the price consumers actually pay for Mounjaro. GoodRx reveals that average retail prices for Mounjaro range from $1,071 to $1,351, excluding any discount promotions or insurance coverage.
Mounjaro’s cost hinges on various factors, including a patient’s insurance coverage, the pharmacy they choose, and whether it has been prescribed for Type 2 diabetes. As of August 2023, it is unlikely that insurance companies will cover Mounjaro for weight loss.
As concerns mount over the cost of tirzepatide, those interested in taking this controversial drug need to consider both the financial implications as well as the potential for harmful side effects Below we go into more detail on side effects and the harm alleged in Mounjaro lawsuits.
What Are Mounjaro Side Effects?
The following are the most reported Mounjaro side effects:
- Constipation
- Diarrhea
- Itching at the injection site
- Loss of appetite
- Nausea
- Redness at the injection site
- Swelling at the injection site
- Tiredness
- Upset stomach
- Vomiting
Serious Mounjaro side effects:
- Decreased/blurred vision
- Change in the amount of urine (signs of kidney problems)
Very serious Mounjaro side effects:
- Nausea/vomiting that doesn't stop
- Severe stomach/abdominal pain (signs of pancreas or gallbladder disease)
In addition to the adverse events listed above, Mounjaro lawsuits allege the following side effects after tirzepatide:
Gastroparesis: A medical condition that disrupts the usual movement of muscles in the stomach, impacting its ability to function properly. Normally, the rhythmic contractions of these muscles help propel food through the digestive system. However, individuals with gastroparesis experience a slowdown or complete failure of stomach motility, resulting in improper emptying of the stomach.
According to the American College of Gastroenterology, drugs that delay stomach emptying may cause gastroparesis.
Gastroenteritis An illness caused by an infection and inflammation in the digestive system. Common signs of gastroenteritis include stomach cramps, diarrhea, and vomiting. The most concerning complication of gastroenteritis is dehydration. In severe cases, individuals may require intravenous fluid therapy, or a "drip," which involves administering fluids directly into the bloodstream through a vein.
Although Mounjaro may cause delayed gastric emptying, which can assist with weight loss, prolonged use of the medication can result in a chronic condition. In fact, the plaintiff in an August 2023 Mounjaro lawsuit claims that excessive vomiting caused by the medication led to her losing her teeth.
The lawsuit further alleges that the makers of Ozempic and Mounjaro acknowledge that gastrointestinal events are well-known side effects of GLP-1 class drugs. However, both Novo Nordisk and Eli Lilly “have downplayed the severity of the gastrointestinal events caused by Ozempic and Mounjaro, never, for example, warning of the risk of gastroparesis or gastroenteritis,” the lawsuit states.
Mounjaro for Weight Loss
While tirzepatide has not been approved for weight loss, that has not stopped Eli Lilly from promoting Mounjaro for weight loss, according to lawsuits.
As of August 2023, the FDA has only approved Mounjaro for the treatment Type 2 diabetes, not weight loss. The drug’s official website says “Mounjaro is not a weight loss drug,” though it uses bold purple letters showing that people taking the drug have “lost up to 25 pounds.” Last October, Eli Lilly announced that the FDA would fast-track its process of examining and approving Mounjaro for adults who are obese or overweight.
We do not know the long-term effects among people taking Mounjaro for weight loss, which is scary because some estimate that tirzepatide will soon overtake semaglutide (generic for Ozempic) in popularity. According to reports, 1 in 10 Americans have taken Ozempic for weight loss. “I don’t think blockbuster would be underselling it,” says Dr. Andrew Kraftson, a clinical associate professor in the division of metabolism, endocrinology, and diabetes at Michigan Medicine.
Is There a Mounjaro Class Action?
At this time, we are unaware of a Mounjaro class action lawsuit. If a Mounjaro class action formed, the litigation would try to secure medical monitoring for people facing future risks after using Mounjaro or seek compensation from Eli Lilly for failing to disclose serious risks associated with tirzepatide.
Individuals alleging gastroparesis or gastroenteritis after taking Mounjaro for weight loss may chose to file a personal injury case against Eli Lilly. These cases will involve distinct damages for each plaintiff and will not be consolidated into a class action, where damages are essentially distributed evenly among members of the class.
In February of 2024, the Judicial Panel on Multidistrict Litigation (JPML) consolidated Mounjaro lawsuits in federal court. An MDL streamlines discovery and pretrial proceedings and functions similarly to a class action, though individual cases are tried separately. As with other defective drug lawsuits, like Zantac for example, some attorneys may choose to file cases in state court if they believe that venue gives their clients a better path toward justice.
Mounjaro VS Ozempic
Mounjaro (tirzepatide) and Ozempic (semaglutide) are in a class of drugs known as incretin mimetics. When combined with diet and exercise, the medications regulate blood sugar levels for adults with type 2 diabetes.
Similarities between Mounjaro and Ozempic:
- Both are administered weekly via subcutaneous injections.
- Both can be costly if paid for out of pocket.
- Both are now widely used for weight loss even though neither drug has received FDA approval specifically for this purpose.
- Both are implicated in weight loss drug lawsuits alleging gastroparesis, gastroenteritis, persistent vomiting, and other serious side effects.
Differences between Mounjaro and Ozempic:
Mounjaro is an Eli Lilly drug. Ozempic is a Novo Nordisk drug.
Mounjaro targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, which are natural incretin hormones. Ozempic exclusively targets GLP-1 receptors. Some have speculated that because Mounjaro targets both PIP and GLP-1 receptors, that may lead to patients losing more weight, though this has not been proven.
Dr. Akshaya Srikanth Bhagavathula, a postdoctoral fellow at the University of Arkansas who has studied tirzepatide, recently told the New York Times that Mounjaro can cause more severe side effects than Ozempic.
Will There be a Mounjaro Settlement?
The litigation is in the early stages now, so we do not know at this time whether there will be a Mounjaro settlement. That said, most mass torts that involve hundreds or thousands of plaintiffs culminate in a settlement. If many people have viable claims and the court does not dismiss the cases, a settlement would be the most likely outcome. But again, it is too early to expect a result in this litigation to come anytime soon.
What is the Mounjaro Lawsuit Payout?
The potential compensation available in a Mounjaro lawsuit will depend on each individual’s claims for damages. These damages are designed to cover a range of expenses and provide compensation for the plaintiff's physical, emotional, and financial losses. Those pursuing a Mounjaro lawsuit may be able to recover:
- Medical Care (Past and Future)
This includes reimbursement for various medical expenses such as hospital stays, medications, surgeries, rehabilitation, and other treatments necessary for the plaintiff's recovery. Both past and future medical expenses can be included.
- Lost Income and Wages (Past and Future)
Another important element of a Mounjaro lawsuit is lost income and wages. If the harm you suffered prevented the plaintiff from fulfilling professional duties or resulted in a significant amount of time missing work, they may be entitled to compensation for the income they lost as well as income they would have earned in the future.
- Pain and Suffering (Past and Future)
Pain and suffering damages are intended to compensate plaintiffs for the physical and emotional anguish they have endured due to the mass tort incident. This includes not only the immediate pain and suffering experienced but also the long-term effects and ongoing emotional distress caused by the Mounjaro side effects.
- Loss of Enjoyment of Life (Past and Future)
If the injuries significantly limit an individual's ability to participate in activities that were previously sources of joy and fulfillment, they may be eligible for damages for loss of enjoyment of life. This type of compensation acknowledges the reduction in the plaintiff's overall quality of life resulting from the harm they suffered.
- Punitive Damages
In some cases, plaintiffs may seek punitive damages in addition to compensatory damages. Punitive damages, also known as exemplary damages, serve a twofold purpose. First, they are meant to punish corporations that have demonstrated willful, malicious, or intentional misconduct. Second, punitive damages aim to deter other companies from engaging in similar wrongful behavior. While not always awarded, punitive damages can be significant.
Who Can File a Mounjaro Lawsuit?
You may qualify for a Mounjaro lawsuit if you:
- Used Mounjaro.
- Were diagnosed with gastroparesis (stomach paralysis), gastroenteritis, persistent vomiting, nausea, or diarrhea.
Lawsuits against Mounjaro and other weight loss drugs allege the warning labels were insufficient, putting consumers at risk of serious harm. Pursuing a Mounjaro lawsuit allows you to seek justice and maximum compensation for your injuries. It also sends Eli Lilly a strong message that putting profit above people comes at a great price.
One thing you need to be aware of: Each state has a statute of limitations that restricts how long you have to file a Mounjaro lawsuit. We advise you to contact a lawyer as soon as possible to ensure your rights are protected.
How to Find the Best Mounjaro Lawyer for Your Case
Finding the best Mounjaro lawyer to represent your legal interests can be a complicated process. Hundreds of law firms show up on a Google search for Mounjaro lawsuits. So how do you know what lawyer is the best fit for you?
Here are some helpful tips when researching law firms to represent you:
- Clear communication: When you speak with a Mounjaro lawyer (or a representative on the legal team), do they give you a clear understanding of your legal rights? Do they take their time to make sure your questions are being answered thoughtfully and with careful consideration? Remember, whoever you hire to represent you is probably going to be on your case for months, if not years. You should feel comfortable with their communication style.
- Demonstrated track record of success: Has the attorney won similar personal injury cases? Has the law firm earned a reputation for securing significant verdicts and settlements against major drug companies? Results may not be everything, but they certainly matter. You want an experienced litigator on your side. offering free consultations, personal compatibility, and a transparent payment structure.
- Transparent fee structure: You should know what you stand to gain by pursuing a Mounjaro lawsuit. This means having the legal team representing you break down the fee structure when you retain them. Mounjaro lawyers represent clients on a contingency fee basis, which means they only make money if they are successful in obtaining compensation on your behalf. But fee agreements can vary between firms. Make sure you know from the beginning what the fee agreement is for your Mounjaro lawsuit.
To find the best Mounjaro attorney for your case, we recommend interviewing multiple law firms. Prioritize experience, success in similar cases, transparent fee structure, and effective communication.
To find out if you are eligible to file a Mounjaro lawsuit and hold Eli Lilly accountable, call (310) 207-3233 today.
